GRFS

Grifols S.A. ADR (GRFS) | Rumor.io

Grifols

GRFS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,660

Bullish sentiment (50-day avg)82%

Price to earnings ratio9.87

Market capitalization5B

Earnings per share0.75

Dividend yield (TTM)5.1%

Revenue (annual)7.5B

Net income (annual)500M

Social

What share of all stock conversation is about GRFS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jul 23

The stock price of GRFS (Grifols, S.A.) is currently $7.88, with a 1.68% increase.
The market appears to be experiencing a bullish breakout setup, with many users loading up on the stock.
There is a sense of urgency among traders, with several users advising to act quickly to capitalize on the potential opportunity.

Generated by AI

Sentiment

Of the messages about GRFS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	66.67% -17.33	81.25% -15.42
Bearish	—	—	33.33% +17.33	18.75% +15.42

Bullish· Jul 23

The company is experiencing bullish pressure, with the stock price rising by 1.68% and the author loading up on the stock, anticipating further growth.
The author is positioning for a breakout, loading up on the stock as the chart turns bullish, and expecting a quick run possible due to the rising momentum.
The stock's bullish signals are stacking, with the author loading up while it's hot, anticipating a surprise move and urging others not to sleep on the opportunity.

Bearish· Jan 9

The company's stock price is vulnerable to short selling, with some individuals expecting a significant decline.
A recent report has raised concerns about the company's debt, which has contributed to a drop in its stock price.
Institutional investors may be selling their shares to retail investors, further depressing the stock's value.

Generated by AI

Topics

Of the messages about GRFS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	0.52%
Controversies	—	0%	0%	0.04%
Analysts	—	0%	0%	33.12%
Earnings	—	0%	0%	0.04%
Macro	—	0%	0%	33.12%
Technical Analysis	—	0%	0%	33.15%

Earnings· Jul 27

Grifols, S.A. reported earnings that met EPS estimates but missed revenue expectations.
The company's earnings report was in-line with EPS estimates, but revenue fell short of expectations.
Grifols, S.A.'s earnings report showed EPS in-line with estimates, but revenue came in lower than anticipated.

Announcements· May 9

Grifols, S.A. (GRFS) has been mentioned in relation to the launch of Boxo Productions, a subsidiary of $NUGN.
NaturalShrimp (SHMP) has appointed new board members, including Thomas Pickens, Paraic Mulgrew, Edward Rashid, and Edward Johnson.
There is no specific announcement related to Grifols, S.A. (GRFS) in the provided messages.

Generated by AI

Community

Of the messages about GRFS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	33.33%	64.42%	50.14%
Newcomers	—	66.67%	35.58%	49.86%

Regulars· Oct 1

Grifols, S.A. has completed the acquisition of a Green Cross fractionation plant in Canada and 11 plasma centers in the U.S., expanding its operations.
Morgan Stanley has maintained an "Overweight" rating for Grifols, S.A., indicating a positive outlook on the company's future performance.
Citigroup has upgraded its rating for Grifols, S.A. to "Neutral" from a previous rating, suggesting a shift in the analyst's assessment of the company's value.

Newcomers· Jul 23

The newcomers are focusing on the bullish pressure and breakout setup in GRFS, with some anticipating a quick run or surprise move.
The new users are loading up on GRFS as they see momentum picking up and a bullish bias taking hold, with some anticipating a breakout.
The users are emphasizing the need to act quickly on the opportunity, warning others not to "sleep on this" and to take advantage of the bullish signals and momentum in GRFS.

Generated by AI

Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple. The group’s ability to turn its plasma based operations into...

3d agoYahoo Finance

Grifols says Canada plasma license suspension has no impact on ongoing operations

6d agoReuters

Grifols Stock: Better Plasma Economics Can Unlock A Discounted Equity (NASDAQ:GRFS)

13d agoSeeking Alpha

OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health

Toronto, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The union that represents Canadian Blood Services (CBS) workers in Ontario is calling for an immediate termination of the blood-plasma collection contract with for-profit Spanish pharmaceutical company Grifols. OPSEU/SEFPO is also calling for an ironclad commitment to ensure that blood and plasma services are never again operated on a for-profit basis. Two people died after donating plasma at Grifols-operated facilities in Winnipeg in October 2025 and J

1mo agoYahoo Finance

After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada

1mo agoThe New York Times

Grifols completes clinical trial for alpha-1 deficiency treatment

1mo agoInvesting.com

Also Discussed

Investors talking about GRFS also mention

#	Name	Attention
1	Capital City Bank Group Inc.CCBG	0%new
2	MOFG - MidWestOne Financial Group, Inc.	——
3	ACNB CorporationACNB	0%0
4	AMNB - American National Bankshares Inc.	——
5	First Northwest Bancorp Common StockFNWB	0%new
6	Kamada Ltd.KMDA	0%0
7	FSFG - First Savings Financial Group, Inc.	——
8	United Fire Group Inc.UFCS	0%0
9	Peoples Bancorp of North Carolina, Inc.PEBK	0%0
10	First Merchants CorporationFRME	0%0

Grifols S.A. ADR

Healthcare
Drug Manufacturers - General

Grifols S.A. ADR is a healthcare and biotechnology asset representing Grifols’ U.S. depositary shares. Grifols is a global specialty plasma therapeutics company focused on the research, development, manufacturing, and distribution of plasma-derived medicines and related biopharmaceutical products. Its core activities span biopharma, diagnostic solutions, bio supplies, and other healthcare services, supporting treatment areas such as immunodeficiencies, bleeding disorders, and hospital-based care. The company also provides diagnostic systems, reagents, and products used in transfusion medicine and clinical laboratories, making it an important supplier to hospitals, blood centers, and healthcare providers. Grifols S.A. ADR gives investors access to a multinational healthcare business whose products and services are deeply embedded in the plasma medicine and diagnostics market.

Website

Location

Parque Empresarial Can Sant Joan

Barcelona, 08174

Spain

Social

What share of all stock conversation is about GRFS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jul 23

The stock price of GRFS (Grifols, S.A.) is currently $7.88, with a 1.68% increase.
The market appears to be experiencing a bullish breakout setup, with many users loading up on the stock.
There is a sense of urgency among traders, with several users advising to act quickly to capitalize on the potential opportunity.

Generated by AI

Sentiment

Of the messages about GRFS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	66.67% -17.33	81.25% -15.42
Bearish	—	—	33.33% +17.33	18.75% +15.42

Bullish· Jul 23

The company is experiencing bullish pressure, with the stock price rising by 1.68% and the author loading up on the stock, anticipating further growth.
The author is positioning for a breakout, loading up on the stock as the chart turns bullish, and expecting a quick run possible due to the rising momentum.
The stock's bullish signals are stacking, with the author loading up while it's hot, anticipating a surprise move and urging others not to sleep on the opportunity.

Bearish· Jan 9

The company's stock price is vulnerable to short selling, with some individuals expecting a significant decline.
A recent report has raised concerns about the company's debt, which has contributed to a drop in its stock price.
Institutional investors may be selling their shares to retail investors, further depressing the stock's value.

Generated by AI

Topics

Of the messages about GRFS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	0.52%
Controversies	—	0%	0%	0.04%
Analysts	—	0%	0%	33.12%
Earnings	—	0%	0%	0.04%
Macro	—	0%	0%	33.12%
Technical Analysis	—	0%	0%	33.15%

Earnings· Jul 27

Grifols, S.A. reported earnings that met EPS estimates but missed revenue expectations.
The company's earnings report was in-line with EPS estimates, but revenue fell short of expectations.
Grifols, S.A.'s earnings report showed EPS in-line with estimates, but revenue came in lower than anticipated.

Announcements· May 9

Grifols, S.A. (GRFS) has been mentioned in relation to the launch of Boxo Productions, a subsidiary of $NUGN.
NaturalShrimp (SHMP) has appointed new board members, including Thomas Pickens, Paraic Mulgrew, Edward Rashid, and Edward Johnson.
There is no specific announcement related to Grifols, S.A. (GRFS) in the provided messages.

Generated by AI

Community

Of the messages about GRFS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	33.33%	64.42%	50.14%
Newcomers	—	66.67%	35.58%	49.86%

Regulars· Oct 1

Grifols, S.A. has completed the acquisition of a Green Cross fractionation plant in Canada and 11 plasma centers in the U.S., expanding its operations.
Morgan Stanley has maintained an "Overweight" rating for Grifols, S.A., indicating a positive outlook on the company's future performance.
Citigroup has upgraded its rating for Grifols, S.A. to "Neutral" from a previous rating, suggesting a shift in the analyst's assessment of the company's value.

Newcomers· Jul 23

The newcomers are focusing on the bullish pressure and breakout setup in GRFS, with some anticipating a quick run or surprise move.
The new users are loading up on GRFS as they see momentum picking up and a bullish bias taking hold, with some anticipating a breakout.
The users are emphasizing the need to act quickly on the opportunity, warning others not to "sleep on this" and to take advantage of the bullish signals and momentum in GRFS.

Generated by AI

Grifols

Social

Jul 23

Bullish· Jul 23

Bearish· Jan 9

Earnings· Jul 27

Announcements· May 9

Regulars· Oct 1

Newcomers· Jul 23

Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings

Grifols says Canada plasma license suspension has no impact on ongoing operations

Grifols Stock: Better Plasma Economics Can Unlock A Discounted Equity (NASDAQ:GRFS)

OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health

After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada

Grifols completes clinical trial for alpha-1 deficiency treatment

Also Discussed

Grifols S.A. ADR

Company Information

Location

Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings

Grifols says Canada plasma license suspension has no impact on ongoing operations

Grifols Stock: Better Plasma Economics Can Unlock A Discounted Equity (NASDAQ:GRFS)

OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health

After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada

Grifols completes clinical trial for alpha-1 deficiency treatment

Also Discussed

Social

Jul 23

Bullish· Jul 23

Bearish· Jan 9

Earnings· Jul 27

Announcements· May 9

Regulars· Oct 1

Newcomers· Jul 23